The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Olmesartan     5-(2-hydroxypropan-2-yl)-2- propyl-3-[[4-[2...

Synonyms: SureCN94037, SureCN677160, RNH-6270, cc-480, CHEBI:48416, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Olmetec

  • Olmesartan also reduced proteinuria and prevented glomerulosclerosis even by the delayed treatment, which was initiated after the podocyte injury appeared [1].
  • Cortical tissue hypoxia in the early phase (4 and 7 d) in remnant kidney rats, sham-operated rats, and animals treated with the angiotensin II receptor blocker (ARB) olmesartan (10 mg/kg per d) was assessed by uptake of a hypoxic probe, pimonidazole, expression of HIF-1alpha, and by increased transcription of hypoxia-responsive genes [2].
  • The role of olmesartan medoxomil in the management of hypertension [3].
  • After 6 months of treatment with olmesartan, intimal hyperplasia was significantly lower than before treatment [4].
  • Moreover, azelnidipine synergistically enhanced the inhibitory action of olmesartan on brain ischemia, suggesting beneficial combined effects of a CCB with an AT1 receptor blocker on ischemic brain damage [5].

High impact information on Olmetec

  • Olmesartan also suppressed lymphocyte proliferation in mice immunized with ovalbumin in alum [6].
  • The acceleration of phenotypic changes of podocytes, proteinuria, and subsequent glomerulosclerosis by heminephrectomy was almost completely inhibited by angiotensin II type 1 receptor (AT1R) blocker olmesartan [1].
  • In contrast, plasma 8-isoprostane 15(S)-8-iso-prostaglandin F(2a) concentration, a biochemical marker of oxidative stress, decreased significantly (P < 0.05) with olmesartan treatment [7].
  • Active plasma renin concentration increased considerably (P < 0.05) with olmesartan therapy but remained unchanged with placebo treatment [7].
  • Six groups of 50 gerbils were treated either with placebo, erythropoietin (intraperitoneally, 5000 IU/kg, 2 and 48 h after stroke), olmesartan (10 mg/kg per day in drinking water started 36 h after stroke), ramipril (2.5 mg/kg per day in drinking water started 36 h after stroke), erythropoietin + olmesartan, or erythropoietin + ramipril [8].

Chemical compound and disease context of Olmetec


Biological context of Olmetec


Anatomical context of Olmetec


Associations of Olmetec with other chemical compounds


Gene context of Olmetec


Analytical, diagnostic and therapeutic context of Olmetec


  1. Angiotensin II Type 1 Receptor Blockade Inhibits the Development and Progression of HIV-Associated Nephropathy in a Mouse Model. Hiramatsu, N., Hiromura, K., Shigehara, T., Kuroiwa, T., Ideura, H., Sakurai, N., Takeuchi, S., Tomioka, M., Ikeuchi, H., Kaneko, Y., Ueki, K., Kopp, J.B., Nojima, Y. J. Am. Soc. Nephrol. (2007) [Pubmed]
  2. Evidence of tubular hypoxia in the early phase in the remnant kidney model. Manotham, K., Tanaka, T., Matsumoto, M., Ohse, T., Miyata, T., Inagi, R., Kurokawa, K., Fujita, T., Nangaku, M. J. Am. Soc. Nephrol. (2004) [Pubmed]
  3. The role of olmesartan medoxomil in the management of hypertension. Unger, T., McInnes, G.T., Neutel, J.M., Böhm, M. Drugs (2004) [Pubmed]
  4. The regressive effect of an angiotensin II receptor blocker on formed fatty streaks in monkeys fed a high-cholesterol diet. Takai, S., Jin, D., Sakaguchi, M., Muramatsu, M., Miyazaki, M. J. Hypertens. (2005) [Pubmed]
  5. The calcium-channel blocker, azelnidipine, enhances the inhibitory action of AT1 receptor blockade on ischemic brain damage. Iwai, M., Chen, R., Ide, A., Iwanami, J., Tomochika, H., Tomono, Y., Mogi, M., Horiuchi, M. J. Hypertens. (2006) [Pubmed]
  6. Angiotensin receptor blockers suppress antigen-specific T cell responses and ameliorate collagen-induced arthritis in mice. Sagawa, K., Nagatani, K., Komagata, Y., Yamamoto, K. Arthritis Rheum. (2005) [Pubmed]
  7. Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes. Fliser, D., Wagner, K.K., Loos, A., Tsikas, D., Haller, H. J. Am. Soc. Nephrol. (2005) [Pubmed]
  8. Synergistic protective effects of erythropoietin and olmesartan on ischemic stroke survival and post-stroke memory dysfunctions in the gerbil. Faure, S., Oudart, N., Javellaud, J., Fournier, A., Warnock, D.G., Achard, J.M. J. Hypertens. (2006) [Pubmed]
  9. Adding hydrochlorothiazide to olmesartan dose dependently improves 24-h blood pressure and response rates in mild-to-moderate hypertension. Sellin, L., Stegbauer, J., Laeis, P., Rump, L.C. J. Hypertens. (2005) [Pubmed]
  10. Olmesartan medoxomil. Warner, G.T., Jarvis, B. Drugs (2002) [Pubmed]
  11. Opposing actions of angiotensin II type 1 and 2 receptors on plasma cholesterol levels in rats. Hirano, T., Ran, J., Adachi, M. J. Hypertens. (2006) [Pubmed]
  12. An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, improves experimental liver fibrosis by suppression of proliferation and collagen synthesis in activated hepatic stellate cells. Kurikawa, N., Suga, M., Kuroda, S., Yamada, K., Ishikawa, H. Br. J. Pharmacol. (2003) [Pubmed]
  13. Additive effects of combined blockade of AT1 receptor and HMG-CoA reductase on left ventricular remodeling in infarcted rats. Lee, T.M., Lin, M.S., Chou, T.F., Chang, N.C. Am. J. Physiol. Heart Circ. Physiol. (2006) [Pubmed]
  14. Angiotensin II infusion increases hepatic triglyceride production via its type 2 receptor in rats. Ran, J., Hirano, T., Adachi, M. J. Hypertens. (2005) [Pubmed]
  15. Population pharmacokinetics of olmesartan following oral administration of its prodrug, olmesartan medoxomil: in healthy volunteers and hypertensive patients. Yoshihara, K., Gao, Y., Shiga, H., Wada, D.R., Hisaoka, M. Clinical pharmacokinetics. (2005) [Pubmed]
  16. The contribution of skeletal muscle tumor necrosis factor-alpha to insulin resistance and hypertension in fructose-fed rats. Togashi, N., Ura, N., Higashiura, K., Murakami, H., Shimamoto, K. J. Hypertens. (2000) [Pubmed]
  17. Calcium Channel Blocker Azelnidipine Reduces Glucose Intolerance in Diabetic Mice via Different Mechanism Than Angiotensin Receptor Blocker Olmesartan. Iwai, M., Li, H.S., Chen, R., Shiuchi, T., Wu, L., Min, L.J., Li, J.M., Tsuda, M., Suzuki, J., Tomono, Y., Tomochika, H., Mogi, M., Horiuchi, M. J. Pharmacol. Exp. Ther. (2006) [Pubmed]
  18. Megalin binds and internalizes angiotensin-(1-7). Gonzalez-Villalobos, R., Klassen, R.B., Allen, P.L., Johanson, K., Baker, C.B., Kobori, H., Navar, L.G., Hammond, T.G. Am. J. Physiol. Renal Physiol. (2006) [Pubmed]
  19. Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity. Furuhashi, M., Ura, N., Takizawa, H., Yoshida, D., Moniwa, N., Murakami, H., Higashiura, K., Shimamoto, K. J. Hypertens. (2004) [Pubmed]
  20. Salutary effects of attenuation of angiotensin II on coronary perivascular fibrosis associated with insulin resistance and obesity. Zaman, A.K., Fujii, S., Goto, D., Furumoto, T., Mishima, T., Nakai, Y., Dong, J., Imagawa, S., Sobel, B.E., Kitabatake, A. J. Mol. Cell. Cardiol. (2004) [Pubmed]
  21. Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats. Igase, M., Strawn, W.B., Gallagher, P.E., Geary, R.L., Ferrario, C.M. Am. J. Physiol. Heart Circ. Physiol. (2005) [Pubmed]
  22. Blood pressure and endocrine effects of single doses of CS-866, a novel angiotensin II antagonist, in salt-restricted hypertensive patients. Püchler, K., Nussberger, J., Laeis, P., Witte, P.U., Brunner, H.R. J. Hypertens. (1997) [Pubmed]
  23. Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice. Suzuki, J., Iwai, M., Li, Z., Li, J.M., Min, L.J., Ide, A., Yoshii, T., Oshita, A., Mogi, M., Horiuchi, M. J. Hypertens. (2005) [Pubmed]
  24. Effects of olmesartan, an AT1 receptor antagonist, on hypoxia-induced activation of ERK1/2 and pro-inflammatory signals in the mouse lung. Tanabe, Y., Morikawa, Y., Kato, T., Kanai, S., Watakabe, T., Nishijima, A., Iwata, H., Isobe, K., Ishizaki, M., Nakayama, K. Naunyn Schmiedebergs Arch. Pharmacol. (2006) [Pubmed]
  25. Protein kinase C and extracellular signal regulated kinase are involved in cardiac hypertrophy of rats with progressive renal injury. Takahashi, H., Takeishi, Y., Miyamoto, T., Shishido, T., Arimoto, T., Konta, T., Miyashita, T., Ito, M., Kubota, I. Eur. J. Clin. Invest. (2004) [Pubmed]
  26. Oatp1b1, oatp1b3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel Angiotensin ii blocker. Nakagomi-Hagihara, R., Nakai, D., Kawai, K., Yoshigae, Y., Tokui, T., Abe, T., Ikeda, T. Drug Metab. Dispos. (2006) [Pubmed]
  27. Pigment-epithelium-derived factor (PEDF) inhibits angiotensin-II-induced vascular endothelial growth factor (VEGF) expression in MOLT-3 T cells through anti-oxidative properties. Yamagishi, S., Matsui, T., Nakamura, K., Yoshida, T., Shimizu, K., Takegami, Y., Shimizu, T., Inoue, H., Imaizumi, T. Microvasc. Res. (2006) [Pubmed]
  28. AT1 receptor mediated augmentation of intrarenal angiotensinogen in angiotensin II-dependent hypertension. Kobori, H., Prieto-Carrasquero, M.C., Ozawa, Y., Navar, L.G. Hypertension (2004) [Pubmed]
  29. Mechanisms of angiotensin II type 1 receptor blocker for anti-atherosclerotic effect in monkeys fed a high-cholesterol diet. Takai, S., Kim, S., Sakonjo, H., Miyazaki, M. J. Hypertens. (2003) [Pubmed]
  30. CS-886, a new angiotensin II type 1 receptor antagonist, ameliorates glomerular anionic site loss and prevents progression of diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rats. Koga, K., Yamagishi, S., Takeuchi, M., Inagaki, Y., Amano, S., Okamoto, T., Saga, T., Makita, Z., Yoshizuka, M. Mol. Med. (2002) [Pubmed]
  31. Olmesartan, a novel AT1 antagonist, suppresses cytotoxic myocardial injury in autoimmune heart failure. Yuan, Z., Nimata, M., Okabe, T.A., Shioji, K., Hasegawa, K., Kita, T., Kishimoto, C. Am. J. Physiol. Heart Circ. Physiol. (2005) [Pubmed]
WikiGenes - Universities